Literature DB >> 20877418

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?

Yoko Yanagisawa, Rachel S Midgley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20877418     DOI： 10.1038/nrclinonc.2010.140

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

Authors:  Fairooz F Kabbinavar; Julie Hambleton; Robert D Mass; Herbert I Hurwitz; Emily Bergsland; Somnath Sarkar
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

4.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Authors:  Niall C Tebbutt; Kate Wilson; Val J Gebski; Michelle M Cummins; Diana Zannino; Guy A van Hazel; Bridget Robinson; Adam Broad; Vinod Ganju; Stephen P Ackland; Garry Forgeson; David Cunningham; Mark P Saunders; Martin R Stockler; Yujo Chua; John R Zalcberg; R John Simes; Timothy J Price
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 5.  Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review.

Authors:  S Welch; K Spithoff; R B Rumble; J Maroun
Journal:  Ann Oncol       Date:  2009-11-25       Impact factor: 32.976

6.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Authors:  Jim Cassidy; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Leonard Saltz
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Authors:  Charles S Fuchs; John Marshall; Edith Mitchell; Rafal Wierzbicki; Vinod Ganju; Mark Jeffery; Joseph Schulz; Donald Richards; Raoudha Soufi-Mahjoubi; Benjamin Wang; José Barrueco
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

10.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Authors:  Bruce J Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.